Nisa Investment Advisors LLC lessened its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.9% during the 4th quarter, HoldingsChannel.com reports. The fund owned 677,357 shares of the healthcare product maker’s stock after selling 13,463 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Abbott Laboratories were worth $38,656,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Rowland & Co. Investment Counsel ADV acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth about $102,000. Heritage Trust Co increased its position in shares of Abbott Laboratories by 10.1% during the 2nd quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock worth $106,000 after purchasing an additional 200 shares during the last quarter. Tributary Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth about $106,000. Thompson Davis & CO. Inc. increased its position in shares of Abbott Laboratories by 17.7% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock worth $120,000 after purchasing an additional 370 shares during the last quarter. Finally, Motco increased its position in shares of Abbott Laboratories by 213.7% during the 2nd quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock worth $140,000 after purchasing an additional 1,962 shares during the last quarter. Institutional investors and hedge funds own 71.22% of the company’s stock.

In other news, Chairman Miles D. White sold 276,886 shares of the business’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $54.41, for a total transaction of $15,065,367.26. Following the completion of the transaction, the chairman now directly owns 3,677,913 shares of the company’s stock, valued at $200,115,246.33. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Stephen R. Fussell sold 13,313 shares of the business’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $62.84, for a total value of $836,588.92. Following the transaction, the executive vice president now directly owns 152,343 shares of the company’s stock, valued at $9,573,234.12. The disclosure for this sale can be found here. Over the last three months, insiders have sold 445,615 shares of company stock valued at $24,666,341. Corporate insiders own 0.76% of the company’s stock.

A number of analysts recently issued reports on ABT shares. Bank of America raised their price objective on Abbott Laboratories from $60.00 to $70.00 in a research report on Wednesday, January 24th. They noted that the move was a valuation call. Jefferies Group reissued a “buy” rating and set a $65.00 price objective on shares of Abbott Laboratories in a research report on Thursday, October 19th. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price objective for the company in a research report on Monday, October 16th. Cowen set a $68.00 price objective on Abbott Laboratories and gave the stock a “buy” rating in a research report on Thursday, October 19th. Finally, Stifel Nicolaus raised their price objective on Abbott Laboratories from $58.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, October 19th. Eight analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Abbott Laboratories currently has an average rating of “Buy” and an average price target of $65.47.

Abbott Laboratories (ABT) opened at $57.17 on Friday. Abbott Laboratories has a 52-week low of $42.31 and a 52-week high of $64.60. The company has a market capitalization of $99,510.16, a PE ratio of 22.87, a PEG ratio of 1.72 and a beta of 1.55. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $0.74 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The business had revenue of $7.59 billion during the quarter, compared to the consensus estimate of $7.38 billion. During the same period in the previous year, the company posted $0.65 earnings per share. The business’s revenue for the quarter was up 42.3% on a year-over-year basis. research analysts predict that Abbott Laboratories will post 2.86 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a dividend of $0.28 per share. The ex-dividend date is Thursday, January 11th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.96%. Abbott Laboratories’s payout ratio is currently 430.79%.

TRADEMARK VIOLATION NOTICE: “Nisa Investment Advisors LLC Has $38.66 Million Stake in Abbott Laboratories (ABT)” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://theolympiareport.com/2018/02/11/nisa-investment-advisors-llc-has-38-66-million-stake-in-abbott-laboratories-abt.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.